Clinical Trials Logo

Refractory Leukemia clinical trials

View clinical trials related to Refractory Leukemia.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04874480 Active, not recruiting - Refractory Leukemia Clinical Trials

Tegavivint for the Treatment of Relapsed or Refractory Leukemia

Start date: September 27, 2021
Phase: Phase 1
Study type: Interventional

This phase I trial is to find out the best dose and side effects of tegavivint in treating patients with leukemia that has come back (relapsed) or does not response to treatment (refractory). Tegavivint may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving tegavivint in combination with decitabine may help control the disease.